ClinicalTrials.govpublic full text
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
eosinophilic asthma, eosinophilic asthma;, benralizumab,, fasenra,, medium-dose inhaled corticosteroid,, long-acting β2-agonist, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 813732
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.